Brainstorm Cell Therapeutics Price to Book Ratio

The latest P/B ratio for BCLI is -0.63. That is below the Healthcare sector average of 6.65. Investors often review this figure alongside Brainstorm Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, BCLI currently prints -0.63 for P/B ratio, while the sector average sits near 6.65. That is roughly 109.4% below the sector mean. Large gaps often invite a closer look at Brainstorm Cell Therapeutics's growth, margins, and balance sheet.

A P/B ratio of -0.63 for Brainstorm Cell Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (6.65) and with BCLI's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting BCLI's P/B ratio (-0.63), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Brainstorm Cell Therapeutics's P/B ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.